Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models

•We have successfully developed a novel SPECT ligand 123/125I-AD-DRK for cheaper diagnostic nuclear medicine imaging of AD and/or non-AD tauopathies.•123/125I-AD-DRK can bind to amyloid and tau aggregates deposited in postmortem brains from the patients with AD and PSP, respectively.•123/125I-AD-DRK...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NeuroImage (Orlando, Fla.) Fla.), 2024-12, Vol.303, p.120947, Article 120947
Hauptverfasser: Rui, Xiyan, Zhao, Xinran, Zhang, Nailian, Ding, Yuzhou, Seki, Chie, Ono, Maiko, Higuchi, Makoto, Zhang, Ming-Rong, Chu, Yong, Wei, Ruonan, Xu, Miaomiao, Cheng, Chao, Zuo, Changjing, Kimura, Yasuyuki, Ni, Ruiqing, Kai, Mototora, Tian, Mei, Yuan, Chunyan, Ji, Bin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•We have successfully developed a novel SPECT ligand 123/125I-AD-DRK for cheaper diagnostic nuclear medicine imaging of AD and/or non-AD tauopathies.•123/125I-AD-DRK can bind to amyloid and tau aggregates deposited in postmortem brains from the patients with AD and PSP, respectively.•123/125I-AD-DRK can visualize mature amyloid and tau aggregates in the living brains of APP23 and rTg4510 mice, respectively. Non-invasive determination of amyloid-β peptide (Aβ) and tau deposition are important for early diagnosis and therapeutic intervention for Alzheimer's disease (AD) and non-AD tauopathies. In the present study, we investigated the capacity of a novel radioiodinated compound AD-DRK (123/125I-AD-DRK) with 50% inhibitory concentrations of 11 nM and 2 nM for Aβ and tau aggregates, respectively, as a single photon emission computed tomography (SPECT) ligand in living brains. In vitro and ex vivo autoradiography with 125I-AD-DRK was performed in postmortem human and two transgenic (Tg) mice lines with either fibrillar Aβ or tau accumulation, APP23 and rTg4510 mice. SPECT imaging of 123I-AD-DRK was performed in APP23 mice to investigate the ability of AD-DRK to visualize fibrillar protein deposition in the living brain. In-vitro autoradiogram of 125I-AD-DRK showed high specific radioactivity accumulation in the temporal cortex and hippocampus of AD patients and the motor cortex of progressive supranuclear palsy (PSP) patients enriched by Aβ and/or tau aggregates. Ex-vivo autoradiographic images also demonstrated a significant increase in 125I-AD-DRK binding in the forebrain of both APP23 and rTg450 mice compared to their corresponding non-Tg littermates. SPECT imaging successfully captured Aβ deposition in the living brain of aged APP23 mice. The present study developed a novel high-contrast SPECT agent for assisting the diagnosis of AD and non-AD tauopathies, likely benefiting from its affinity for both fibrillar Aβ and tau.
ISSN:1053-8119
1095-9572
1095-9572
DOI:10.1016/j.neuroimage.2024.120947